.jpg)
SECURE CAR-NK cell therapeutical
We designed and generated tumor antigen-specific, "NK-cell-optimized CAR" modified NK cell therapeuticals that can become self-activated in the inhibitory tumor microenvironment via a constitutively expressed cytokine Switch Receptor and activate effector cells that are present in the suppressive milieu via an NFAT promoter-controlled cytokine secretion. Our Self-Enhancing and Community UpREgulating CAR NK (SECURE CAR NK) cells recruit a broad spectrum of effector cells locally, resulting in enhanced antitumor effects.
SECURE CAR NK cells represent a next-generation, off-the-shelf cellular immunotherapy designed for the treatment of solid tumors that are resistant to current CAR T and CAR NK approaches. By becoming self-activated in the inhibitory tumor microenvironment and inducing local cytokine secretion that recruits and boosts endogenous immune cells, they can initiate a broad and potent antitumor response even in immunosuppressive or “cold” tumors. This makes the technology suitable as a standalone therapy or in combination with existing treatments such as checkpoint inhibitors, radiotherapy, or oncolytic viruses. The modular design allows rapid adaptation to different tumor antigens and cytokines, enabling a scalable platform for developing diverse NK-based therapeutics.
Our product’s practical application lies in providing a powerful, microenvironment-responsive therapy with the potential to improve efficacy, accessibility, and durability of immune treatments for solid and heterogeneous cancers.